NASDAQ:TNGX Tango Therapeutics Q1 2025 Earnings Results & Report $26.22 +1.92 (+7.88%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more. Tango Therapeutics missed analyst expectations on both earnings and revenue in its Q1 2025 results, released May 12, 2025. The company reported EPS of -$0.36 versus the -$0.34 consensus estimate, while revenue of $5.39 million fell short of the $6.73 million estimate by $1.33 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 12, 2025TimeBefore Market OpensConference Call9:30 AM ET Tango Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS -$0.34Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersTango Therapeutics Revenue ResultsActual Revenue$5.39 millionExpected Revenue$6.73 millionBeat/MissMissed by -$1.33 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tango Therapeutics Q1 2025 Earnings FAQ Did Tango Therapeutics beat earnings estimates for Q1 2025? Tango Therapeutics (NASDAQ:TNGX) reported earnings of -$0.36 per share for Q1 2025, missing the consensus estimate of -$0.34. The report was announced on Monday, May 12, 2025. What was Tango Therapeutics' revenue for Q1 2025? Tango Therapeutics reported revenue of $5.39 million for Q1 2025, against a consensus estimate of $6.73 million. Tango Therapeutics Earnings HeadlinesJPMorgan Chase & Co. Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock PriceNovember 11 at 4:05 AM | americanbankingnews.comTango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 9 at 12:11 PM | marketscreener.comMToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsNovember 9 at 7:00 AM | globenewswire.comTango, Erasca Open Phase 1/2 Combination Trial Enrollment In Pancreatic And Lung CancersNovember 5, 2026 | rttnews.comTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015November 4, 2026 | globenewswire.comSee More Tango Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email. Email Address About Tango TherapeuticsTango Therapeutics (NASDAQ:TNGX) is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations. Founded in 2017, Tango was established to apply advances in cancer genetics and functional genomics to drug discovery. Its work is focused on oncology, with programs intended for patients whose tumors have molecular features that may make them susceptible to targeted treatment.View Tango Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandThe Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center Ambitions3 Stocks Wall Street Likes More Than the Market DoesD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
